Detection of BRCA1/2 mutations in circulating tumor DNA from patients with ovarian cancer

Approximately 25% of patients with ovarian cancer harbor a pathogenic BRCA1/2 mutation that has been associated with favorable responses for targeted therapy with poly (ADP-ribose) polymerase 1 (PARP1) inhibitors compared to wild-type individuals. The overall frequency of germline and somatic BRCA1/...

Descripción completa

Detalles Bibliográficos
Autores principales: Ratajska, Magdalena, Koczkowska, Magdalena, Żuk, Monika, Gorczyński, Adam, Kuźniacka, Alina, Stukan, Maciej, Biernat, Wojciech, Limon, Janusz, Wasąg, Bartosz
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5731877/
https://www.ncbi.nlm.nih.gov/pubmed/29254167
http://dx.doi.org/10.18632/oncotarget.20722

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5731877/
https://www.ncbi.nlm.nih.gov/pubmed/29254167
http://dx.doi.org/10.18632/oncotarget.20722

Ejemplares similares